CLDN4 and endometrial cancer: (149) demonstrated that type II endometrial cancer cells with high CLDN3 and CLDN4 expression could be effectively targeted using intraperitoneal administration of Clostridium perfringens enterotoxin (CPE) in murine xenograft models.